References
- Martin GS, Mannino DM, Eaton S, . The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348: 1546–54
- Wisplinghoff H, Bischoff T, Tallent SM, . Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39: 309–17
- Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49: 3640–5
- Golan Y, Wolf MP, Pauker SG, . Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005;143: 857–69
- Wilson LS, Reyes CM, Stolpman M, . The direct cost and incidence of systemic fungal infections. Value Health 2002;5: 26–34
- Anaissie EJ, Darouiche RO, Abi-Said D, . Management of invasive Candidal infections: results of a prospective, randomised multicentre study of fluconazole versus amphotericin B and review of the literature. Clin Inf Diseases 1996;23: 964–72
- Prentice HG, Hann IM, Herbrecht R, . A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98: 711–8
- Walsh TJ, Finberg RW, Arndt C, . Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340: 764–71
- Kuse ER, Chetchotisakd P, da Cunha CA, . Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369: 1519–27
- Mora-Duarte J, Betts R, Rotstein C, . Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347: 2020–9
- Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Methods for the evaluation of health care programmes. Oxford: Oxford medical publications, Oxford University Press: 1999
- Goeree R, Burke N, O'Reilly D, . Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23: 671–82
- Willke RJ, Glick HA, Polsky D, . Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998;7: 481–93
- Rote Liste® Online. Rote Liste® Service GmbH. Frankfurt/Main, Germany 2006 Available from http://www.roteliste.de/Online [Last accessed 06 Nov 2006]
- Gelbe Liste Pharmaindex. Medizinische Medien Informations GmbH. Neu-Isenburg, Germany 2006 Available from http://www.gelbeliste.de [Last accessed 06 Nov 2006]
- Deutsche Internet Apotheke. Martinus-Apotheke. Erftstadt, Germany 2006 Available from http://www.g-drg.de [Last accessed 06 Nov 2006]
- G-DRG Browser Version 2.4. Siegburg, Germany: InEK gGmbH. Available from http://www.g-drg.de [Last accessed 06 Nov 2006]
- Clade H. Krankenhaus-Management: Kompetenzzentren sind zukunftsträchtig. Deutsches Ärzteblatt 101, Ausgabe 41 vom 08.10.2004, Seite A-2724. Available from http://www.aerzteblatt.de [Last accessed 05 Mar 2007]
- Einheitlicher Bewertungsmaßstab. Kassenärztliche Bundesvereinigung. Berlin, Germany 2006 Available from http://www.kbv.de/ebm2000plus/EBMGesamt.htm [Last accessed 06 Nov 2006]
- Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17: 479–500
- Jansen JP, Kern WV, Cornely OA, . Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9: 12–23
- Wingard JR, White MH, Anaissie E, . A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31: 1155–63